Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous stromal vascular fraction + platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Black Tie Medical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-ovarian Injection
01
Overview
This investigational autologous cell-based therapy, developed by Black Tie Medical, is designed for ovarian rejuvenation in patients with premature ovarian failure, perimenopause, and menopause. The treatment consists of a combination of autologous stromal vascular fraction (SVF)—derived from the patient's adipose tissue via lipoaspiration—and platelet-rich plasma (PRP) obtained from the patient's blood. The SVF component is a heterogeneous mixture containing adipose-derived stem cells, endothelial progenitor cells, pericytes, fibroblasts, and immune cells, which can be administered as tissue SVF (tSVF) or enzymatically digested cellular SVF (cSVF). The therapy is delivered via imaging-guided intra-ovarian injection and aims to restore hormonal function and regenerate ovarian tissue through the paracrine effects of stem cells and growth factors. It is currently being evaluated in the Phase 1 OVAR-REJUV clinical trial.
- Other names
- tSVF + PRPcSVF + PRPCell Enriched tSVF + PRPSVF + PRPOvarian Rejuvenation with PRP and SVF
Beyond the preview
Go deeper on autologous stromal vascular fraction + platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous stromal vascular fraction + platelet-rich plasma.